Skip to main content
. 2020 Feb 18;11(7):699–726. doi: 10.18632/oncotarget.27487

Figure 3. DNA-PK inhibitors repress HIV transcription by restricting RNAP II CTD phosphorylation.

Figure 3

(A) Jurkat cells and (C) U937 cells were treated with increasing concentrations of the DNA-PK inhibitor NU7441 and then activated with TNF-α (10 ng/ml) for 3 hours. The cells were harvested, and nuclear extracts were assessed through western blot. The phosphorylation state of carboxyl terminal domain (CTD) of RNA polymerase II (RNAP II) was assessed through western blot using antibodies that are specific for RNAP II and its phosphorylated forms (Ser2 and Ser5). HDAC1 was used as loading control. The presented data is one representative western blot analysis out of three. Densitometric analyses were performed on western blot bands using ImageJ software for both (B) Jurkat cells and (D) U937 cells. The results represent the Mean ± SD of three different independent assays. Statistical significance is set as p < 0.05 (*), 0.01 (**), or 0.001 (***) compared to stimulated, but without DNA-PK inhibitor.